Literature DB >> 32163116

Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal Imaging.

Cyril Dutheil1,2, Mélanie Le Goff1, Audrey Cougnard-Grégoire1, Sarra Gattoussi1,2, Jean-François Korobelnik1,2, Marie-Bénédicte Rougier1,2, Cédric Schweitzer1,2, Cécile Delcourt1, Marie-Noëlle Delyfer1,2.   

Abstract

Importance: Although retinal multimodal imaging is needed for diagnosing reticular pseudodrusen (RPD), the incidence of RPD in the general population typically has been assessed only using fundus photographs, which may underestimate their incidence.
Objectives: To describe the incidence of RPD using retinal color photographs, spectral-domain optical coherence tomography scans, fundus autofluorescence, and near-infrared reflectance images among individuals 77 years of age or older and to analyze the associated risk factors of RPD. Design, Setting, and Participants: The ALIENOR (Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires) Study is a cohort of French individuals 77 years of age or older. Data for this study were collected between February 22, 2011, and February 15, 2017, with a mean (SD) follow-up of 3.7 (1.0) years (range, 1.2-5.6 years). At baseline, 501 individuals were eligible to participate. Of 1002 eyes, 197 had prevalent RPD, advanced age-related macular degeneration, or ungradable images. Of the remaining 805 eyes, 333 were missing follow-up data; therefore, the statistical analyses included data from 472 eyes. Data management and statistical analyses were performed between March 15, 2017, and April 5, 2019. Main Outcomes and Measures: Reticular pseudodrusen were considered as present if detected by at least 2 of the following imaging methods: color fundus photographs, fundus autofluorescence, near-infrared reflectance, and spectral-domain optical coherence tomography images.
Results: Of the 472 eyes analyzed, 263 (55.7%) were from female participants, and the mean (SD) age was 81.9 (3.2) years. Forty-three eyes developed RPD, corresponding to an annual incidence rate of 2.9% (95% CI, 1.9%-4.4%) per participant and an estimated 5-year risk of 13.5%. In multivariable analysis, 4 risk factors of incident RPD were identified: subfoveal choroidal thinning (hazard ratio [HR], 0.99; 95% CI, 0.99-1.00 per 10-μm decrease in thickness; P = .02) and the presence of the minor allelic variants rs10490924 for ARMS2 (HR, 3.57; 95% CI, 1.80-7.10; P < .001), rs1061170 for CFH (HR, 2.12; 95% CI, 1.02-4.41; P = .04), and rs10468017 for LIPC (HR, 2.57; 95% CI, 1.37-4.82; P = .003). Lipophilic statin therapy was associated with a lower incidence of RPD (HR, 0.13; 95% CI, 0.02-0.74; P = .02). Conclusions and Relevance: With the use of multimodal imaging, the RPD incidence rate was higher than previously reported in other population-based studies using fundus color images. Individuals with subfoveal choroidal thinning or carrying minor allelic variants for ARMS2, CFH, or LIPC had an increased risk for RPD, whereas lipophilic statin therapy was associated with a lower incidence.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32163116      PMCID: PMC7068673          DOI: 10.1001/jamaophthalmol.2020.0266

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  58 in total

1.  Complement factor H polymorphism in age-related macular degeneration.

Authors:  Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

2.  Outer retinal atrophy after regression of subretinal drusenoid deposits as a newly recognized form of late age-related macular degeneration.

Authors:  Richard F Spaide
Journal:  Retina       Date:  2013-10       Impact factor: 4.256

3.  Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).

Authors:  Benjamin M Neale; Jesen Fagerness; Robyn Reynolds; Lucia Sobrin; Margaret Parker; Soumya Raychaudhuri; Perciliz L Tan; Edwin C Oh; Joanna E Merriam; Eric Souied; Paul S Bernstein; Binxing Li; Jeanne M Frederick; Kang Zhang; Milam A Brantley; Aaron Y Lee; Donald J Zack; Betsy Campochiaro; Peter Campochiaro; Stephan Ripke; R Theodore Smith; Gaetano R Barile; Nicholas Katsanis; Rando Allikmets; Mark J Daly; Johanna M Seddon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Models for longitudinal data: a generalized estimating equation approach.

Authors:  S L Zeger; K Y Liang; P S Albert
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

5.  Age-related macular degeneration and cognitive impairment show similarities in changes of neutral lipids in peripheral blood mononuclear cells.

Authors:  Enrico Peiretti; Antonella Mandas; Claudia Abete; Michela Vinci; Stefania Piludu; Maura Casu; Giulia Caminiti; Sandra Dessì; Maurizio Fossarello
Journal:  Exp Eye Res       Date:  2014-05-02       Impact factor: 3.467

6.  Clinical features and long-term progression of reticular pseudodrusen in age-related macular degeneration: findings from a multicenter cohort.

Authors:  J Q Gil; J P Marques; R Hogg; C Rosina; M L Cachulo; A Santos; G Staurenghi; U Chakravarthy; R Silva
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

7.  Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study.

Authors:  Paul Mitchell; Jie Jin Wang; Suriya Foran; Wayne Smith
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

8.  Localized reticular pseudodrusen and their topographic relation to choroidal watershed zones and changes in choroidal volumes.

Authors:  Florian Alten; Christoph R Clemens; Peter Heiduschka; Nicole Eter
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-07       Impact factor: 4.799

9.  Peripheral retinal drusen and reticular pigment: association with CFHY402H and CFHrs1410996 genotypes in family and twin studies.

Authors:  Johanna M Seddon; Robyn Reynolds; Bernard Rosner
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-20       Impact factor: 4.799

10.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

View more
  6 in total

1.  Reticular Pseudodrusen: The Third Macular Risk Feature for Progression to Late Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report 30.

Authors:  Elvira Agrón; Amitha Domalpally; Catherine A Cukras; Traci E Clemons; Qingyu Chen; Zhiyong Lu; Emily Y Chew; Tiarnan D L Keenan
Journal:  Ophthalmology       Date:  2022-05-31       Impact factor: 14.277

Review 2.  Subretinal drusenoid deposits: An update.

Authors:  Manuel Monge; Adriana Araya; Lihteh Wu
Journal:  Taiwan J Ophthalmol       Date:  2022-05-26

3.  Genetic and environmental risk factors for reticular pseudodrusen in the EUGENDA study.

Authors:  Lebriz Altay; Sandra Liakopoulos; Aileen Berghold; Kerstin-Daniela Rosenberger; Angela Ernst; Anita de Breuk; Anneke I den Hollander; Sascha Fauser; Tina Schick
Journal:  Mol Vis       Date:  2021-12-31       Impact factor: 2.367

4.  Age-related macular degeneration eyes presenting with cuticular drusen and reticular pseudodrusen.

Authors:  Je Moon Yoon; Dong Hoon Shin; Mingui Kong; Don-Il Ham
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

5.  Phenotypic Expression of CFH Rare Variants in Age-Related Macular Degeneration Patients in the Coimbra Eye Study.

Authors:  Cláudia Farinha; Patrícia Barreto; Rita Coimbra; Adela Iutis; Maria Luz Cachulo; José Cunha-Vaz; Yara T E Lechanteur; Carel B Hoyng; Rufino Silva
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

6.  Longitudinal choriocapillaris changes in the presence of reticular pseudodrusen.

Authors:  Christoph R Clemens; Jost L Lauermann; Boris Schmitz; Nicole Eter; Florian Alten
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.